Clinical Trials
93 trialsLong-Term Longitudinal QoL in Patients Undergoing EEA
Ohio State University
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing
National Institutes of Health Clinical Center (CC)
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
National Institutes of Health Clinical Center (CC)
AG-120 in People With IDH1 Mutant Chondrosarcoma
Memorial Sloan Kettering Cancer Center
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Memorial Sloan Kettering Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Vismodegib in Treating Patients With Advanced Chondrosarcomas
National Cancer Institute (NCI)
Clinical Applicability of Liquid Biopsy in Chondrosarcoma
Medical University of Graz
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Mayo Clinic
Proton Beam Therapy for Chondrosarcoma
M.D. Anderson Cancer Center
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Servier
REGOSTA
Centre Leon Berard
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
Ricoh USA, Inc.
ADER
Istituto Ortopedico Rizzoli
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
Quironsalud
CIRCLE
Istituto Ortopedico Rizzoli
Diagnostic and Therapeutic Targets in Cartilaginous Tumours
St. Anne's University Hospital Brno, Czech Republic
VARTUTRACE
Var2 Pharmaceuticals
Proton Radiation for Chordomas and Chondrosarcomas
Abramson Cancer Center at Penn Medicine
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
University of Iowa
REGOBONE
UNICANCER
PRIMHADRON
Hospices Civils de Lyon
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Medical College of Wisconsin
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
ROOT
Taproot Health
Grade 2 Chondrosarcoma Treated by Intralesional Curettage: Follow-up vs Resection
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
BETA-PRIME
EpicentRx, Inc.
P1V2
Centre Antoine Lacassagne
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Fred Hutchinson Cancer Center
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
Osteosarcoma
Stanford University
CHIPT
Leiden University Medical Center
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Tracon Pharmaceuticals Inc.
Understanding Engagement Trends in Chondrosarcoma Clinical Trials
Power Life Sciences Inc.
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Emerald Clinical Inc.
A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Genentech, Inc.
TANOs
Université de Reims Champagne-Ardenne
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
AIAC
Peking University People's Hospital
TQBSP
Peking University People's Hospital
Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma
Washington University School of Medicine
MACIST
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)